Chemical Company of Malaysia

Pharmaceuticals Leader Growing through Innovation

malaysia_ccmThe Chemical Company of Malaysia (CCM) Pharmaceuticals Division serves as a benchmark in Malaysia’s rapidly expanding pharmaceuticals sector. The division develops, manufactures and markets world-class generic and branded pharmaceuticals products and has particular expertise in the niche therapeutic areas of oncology, biosimilars and vaccines. The division includes CCM Pharmaceuticals, having leading over-the-counter (OTC) brands like Champs, Proviton, Flavettes and Naturalle; CCM Duopharma Biotech (listed on Bursa Malaysia), a leader in Small Volume Injectables (SVI) and dental cartridges; and Innovax, the division’s research and development arm.

CCM Pharmaceuticals Division has gained a 20% share of Malaysia’s generic pharmaceuticals market and has also established a strong presence in Singapore, the Philippines, Indonesia and Vietnam. It has achieved a number of “firsts”, including opening Malaysia’s first SVI, dental cartridge and sterile ocular products plant; producing the first patented controlled release mini tabs in capsules; and creating the first Intermediate Bulk Container plant. CCM Pharmaceuticals also is the first GMP Pharmaceutical certified manufacturer to obtain the renowned Halal Malaysia certification for its pharmaceutical products in 1999 and has recently received the Halal Pharmaceuticals certification based on World’s First Halal Pharmaceutical Standard MS2424:2012.

Ambitious future goals

Group Managing Director Amirul Feisal Wan Zahir explains that CCM Pharmaceuticals Division’s future goals include expanding its production of fill and finish human vaccines, opening a production facility for biosimilars, and manufacturing high potency active pharmaceutical ingredients for oncology treatments.

The division’s Duopharma Biotech has seen particularly strong growth and is steadily increasing its focus on biologics and biosimilars. It has launched a biologics ‘fill and finish’ line at its factory in Klang and is working with a Korean company on the biosimilar EPO (erythropoietin). CCM Pharmaceuticals Division manufactures its products in three plants in Malaysia and exports around 10% of its production, mainly to the ASEAN markets, although it is eyeing Australia and the Middle East.

CCM Pharmaceuticals Division has made a long term commitment to Malaysia and supports several corporate responsibility projects. Mr. Amirul Feisal concludes, “CCM Pharmaceuticals Division will continue to strive to be environmental friendly, to maintain the highest international standards, to develop its human resources and to help position Malaysia as a regional and global pharmaceuticals hub.”